Cargando…
Comparison of the Predictive Power of a Combination versus Individual Biomarker Testing in Non–Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors
PURPOSE: Since tumor mutational burden (TMB) and gene expression profiling (GEP) have complementary effects, they may have improved predictive power when used in combination. Here, we investigated the ability of TMB and GEP to predict the immunotherapy response in patients with non–small cell lung c...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Cancer Association
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9016300/ https://www.ncbi.nlm.nih.gov/pubmed/34237208 http://dx.doi.org/10.4143/crt.2021.583 |
_version_ | 1784688501118205952 |
---|---|
author | Kim, Hyojin Kwon, Hyun Jung Kim, Eun Sun Kwon, Soohyeon Suh, Kyoung Jin Kim, Se Hyun Kim, Yu Jung Lee, Jong Seok Chung, Jin-Haeng |
author_facet | Kim, Hyojin Kwon, Hyun Jung Kim, Eun Sun Kwon, Soohyeon Suh, Kyoung Jin Kim, Se Hyun Kim, Yu Jung Lee, Jong Seok Chung, Jin-Haeng |
author_sort | Kim, Hyojin |
collection | PubMed |
description | PURPOSE: Since tumor mutational burden (TMB) and gene expression profiling (GEP) have complementary effects, they may have improved predictive power when used in combination. Here, we investigated the ability of TMB and GEP to predict the immunotherapy response in patients with non–small cell lung cancer (NSCLC) and assessed if this combination can improve predictive power compared to that when used individually. MATERIALS AND METHODS: This retrospective cohort study included 30 patients with NSCLC who received immune checkpoint inhibitors (ICI) therapy at the Seoul National University Bundang Hospital. programmed cell death-ligand-1 (PD-L1) protein expression was assessed using immunohistochemistry, and TMB was measured by targeted deep sequencing. Gene expression was determined using NanoString nCounter analysis for the PanCancer IO360 panel, and enrichment analysis were performed. RESULTS: Eleven patients (36.7%) showed a durable clinical benefit (DCB), whereas 19 (63.3%) showed no durable benefit (NDB). TMB and enrichment scores (ES) showed significant differences between the DCB and NDB groups (p=0.044 and p=0.017, respectively); however, no significant correlations were observed among TMB, ES, and PD-L1. ES was the best single biomarker for predicting DCB (area under the curve [AUC], 0.794), followed by TMB (AUC, 0.679) and PD-L1 (AUC, 0.622). TMB and ES showed the highest AUC (0.837) among other combinations (AUC [TMB and PD-L1], 0.777; AUC [PD-L1 and ES], 0.763) and was similar to that of all biomarkers used together (0.832). CONCLUSION: The combination of TMB and ES may be an effective predictive tool to identify patients with NSCLC patients who would possibly benefit from ICI therapies. |
format | Online Article Text |
id | pubmed-9016300 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Korean Cancer Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-90163002022-04-27 Comparison of the Predictive Power of a Combination versus Individual Biomarker Testing in Non–Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors Kim, Hyojin Kwon, Hyun Jung Kim, Eun Sun Kwon, Soohyeon Suh, Kyoung Jin Kim, Se Hyun Kim, Yu Jung Lee, Jong Seok Chung, Jin-Haeng Cancer Res Treat Original Article PURPOSE: Since tumor mutational burden (TMB) and gene expression profiling (GEP) have complementary effects, they may have improved predictive power when used in combination. Here, we investigated the ability of TMB and GEP to predict the immunotherapy response in patients with non–small cell lung cancer (NSCLC) and assessed if this combination can improve predictive power compared to that when used individually. MATERIALS AND METHODS: This retrospective cohort study included 30 patients with NSCLC who received immune checkpoint inhibitors (ICI) therapy at the Seoul National University Bundang Hospital. programmed cell death-ligand-1 (PD-L1) protein expression was assessed using immunohistochemistry, and TMB was measured by targeted deep sequencing. Gene expression was determined using NanoString nCounter analysis for the PanCancer IO360 panel, and enrichment analysis were performed. RESULTS: Eleven patients (36.7%) showed a durable clinical benefit (DCB), whereas 19 (63.3%) showed no durable benefit (NDB). TMB and enrichment scores (ES) showed significant differences between the DCB and NDB groups (p=0.044 and p=0.017, respectively); however, no significant correlations were observed among TMB, ES, and PD-L1. ES was the best single biomarker for predicting DCB (area under the curve [AUC], 0.794), followed by TMB (AUC, 0.679) and PD-L1 (AUC, 0.622). TMB and ES showed the highest AUC (0.837) among other combinations (AUC [TMB and PD-L1], 0.777; AUC [PD-L1 and ES], 0.763) and was similar to that of all biomarkers used together (0.832). CONCLUSION: The combination of TMB and ES may be an effective predictive tool to identify patients with NSCLC patients who would possibly benefit from ICI therapies. Korean Cancer Association 2022-04 2021-07-07 /pmc/articles/PMC9016300/ /pubmed/34237208 http://dx.doi.org/10.4143/crt.2021.583 Text en Copyright © 2022 by the Korean Cancer Association https://creativecommons.org/licenses/by-nc/4.0/This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Kim, Hyojin Kwon, Hyun Jung Kim, Eun Sun Kwon, Soohyeon Suh, Kyoung Jin Kim, Se Hyun Kim, Yu Jung Lee, Jong Seok Chung, Jin-Haeng Comparison of the Predictive Power of a Combination versus Individual Biomarker Testing in Non–Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors |
title | Comparison of the Predictive Power of a Combination versus Individual Biomarker Testing in Non–Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors |
title_full | Comparison of the Predictive Power of a Combination versus Individual Biomarker Testing in Non–Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors |
title_fullStr | Comparison of the Predictive Power of a Combination versus Individual Biomarker Testing in Non–Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors |
title_full_unstemmed | Comparison of the Predictive Power of a Combination versus Individual Biomarker Testing in Non–Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors |
title_short | Comparison of the Predictive Power of a Combination versus Individual Biomarker Testing in Non–Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors |
title_sort | comparison of the predictive power of a combination versus individual biomarker testing in non–small cell lung cancer patients treated with immune checkpoint inhibitors |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9016300/ https://www.ncbi.nlm.nih.gov/pubmed/34237208 http://dx.doi.org/10.4143/crt.2021.583 |
work_keys_str_mv | AT kimhyojin comparisonofthepredictivepowerofacombinationversusindividualbiomarkertestinginnonsmallcelllungcancerpatientstreatedwithimmunecheckpointinhibitors AT kwonhyunjung comparisonofthepredictivepowerofacombinationversusindividualbiomarkertestinginnonsmallcelllungcancerpatientstreatedwithimmunecheckpointinhibitors AT kimeunsun comparisonofthepredictivepowerofacombinationversusindividualbiomarkertestinginnonsmallcelllungcancerpatientstreatedwithimmunecheckpointinhibitors AT kwonsoohyeon comparisonofthepredictivepowerofacombinationversusindividualbiomarkertestinginnonsmallcelllungcancerpatientstreatedwithimmunecheckpointinhibitors AT suhkyoungjin comparisonofthepredictivepowerofacombinationversusindividualbiomarkertestinginnonsmallcelllungcancerpatientstreatedwithimmunecheckpointinhibitors AT kimsehyun comparisonofthepredictivepowerofacombinationversusindividualbiomarkertestinginnonsmallcelllungcancerpatientstreatedwithimmunecheckpointinhibitors AT kimyujung comparisonofthepredictivepowerofacombinationversusindividualbiomarkertestinginnonsmallcelllungcancerpatientstreatedwithimmunecheckpointinhibitors AT leejongseok comparisonofthepredictivepowerofacombinationversusindividualbiomarkertestinginnonsmallcelllungcancerpatientstreatedwithimmunecheckpointinhibitors AT chungjinhaeng comparisonofthepredictivepowerofacombinationversusindividualbiomarkertestinginnonsmallcelllungcancerpatientstreatedwithimmunecheckpointinhibitors |